The treatment is for patients whose non-small cell lung cancer is progressing despite platinum-based therapy.
The label, assigned for the third time to Enhertu, speeds up development and regulatory review of candidates for life-threatening conditions which are lacking treatment.
In a separate announcement, the FTSE 100-listed pharma giant said Bevespi Aerosphere was approved in China to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Bevespi Aerosphere is already approved in countries such as the US, EU and Japan for the long-term maintenance treatment of moderate to very severe COPD.
Shares rose 2% to 8,825p on Monday morning.
Published at Mon, 18 May 2020 08:38:00 +0000-AstraZeneca’s Enhertu fast-tracked for lung cancer treatment